Recommended

Discover the latest breakthroughs in environmental monitoring when you download our latest brand report! Get your free copy today!
Explore innovative, purpose-built AI solutions that elevate compliance and efficiency in quality and manufacturing operations.
Explore how lipid formulations in softgels can enhance drug absorption and bioavailability in this upcoming webinar!
Discover approaches to advance manufacturing processes such as continuous manufacturing, address key manufacturing challenges and optimise product quality at our upcoming webinar – Register now!
EPR’s latest Pharma Horizons report explores the latest advances in cell and gene therapy for quality control, manufacturing, analytical development and more – READ MORE
Register for this webinar to learn about impurity control in pharmaceutical waters! Coming soon!
View our brand new Guide to Testing for 2025!

List view / Grid view

Articles

Finding novel targets for anticancer target discovery

9 May 2010 | By Wolfgang Link, Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas (CNIO)

Advances in our understanding of the molecular basis of cancer together with novel approaches to interfere with signal transduction pathways have opened new horizons for anticancer target discovery. In particular, the image based large scale analysis of cellular phenotypes that arise from genetic or chemical perturbations paved the way for…

SBS Biopharmaceuticals Symposium: Exploring synergies across drug formats

9 May 2010 | By EPR

Biopharmaceuticals is a rapidly growing sector of the pharmaceutical industry. Major pharmaceutical companies have recognised this trend in recent years and defined ambitious targets for the proportion of their pipeline that is expected to be filled by novel biopharmaceuticals. It is inevitable that many of the scientists involved with small-molecule…

drug discovery & drug development
drug discovery & drug development

Implementation of appropriate assays and HTS technologies in drug discovery

9 May 2010 | By Sheraz Gul, Vice President, European ScreeningPort GmbH

In this article, an overview regarding advances in assay formats for specific target classes and options that should be considered when considering hardware will be given. There has been a significant growth in the assay and automation technologies that are available for compound screening activities and it is essential to…

The 58th ASMS Conference on Mass Spectrometry and Allied Topics

9 May 2010 | By EPR

The American Society for Mass Spectrometry (ASMS) was formed in 1969 to promote and disseminate knowledge of mass spectrometry and allied topics. Membership includes over 7,500 scientists involved in research and development. Members come from academic, industrial and governmental laboratories. Their interests include advancement of techniques and instrumentation in mass…

‘Pharmaceutical Industry / University’ R&D collaboration on Process Analytical Technologies

9 May 2010 | By Professor Nicolas Abatzoglou, Chair, PAT in Pharmaceutical Engineering, Department of Chemical and Biotechnological Engineering, Université de Sherbrooke

Process analytical technologies (PAT) are mature and well advanced in the classical chemical industry. Many successful industry/university R&D collaborations are aimed at the development of analytical methods and their application in process control. However, PAT in the pharmaceutical industry is a rather new field. It is precisely this latter reality…

ISSCR 8th Annual Meeting: International Society for Stem Cell Research

9 May 2010 | By EPR

The ISSCR Annual Meeting offers inspired research, new perspectives and networking with stem cell professionals from around the world. It creates a platform for the exchange of theoretical and applied information and skills, providing delegates with perspective, training and a forum to analyse the latest data.

Figure 1
Figure 1

Turn back the clock and be healed Induced pluripotent stem cells and their future impact on drug discovery and regenerative medicine

9 May 2010 | By Paul D. Andrews, Drug Discovery Unit, College of Life Sciences, University of Dundee

They are only four years old and are getting everyone very excited; they were Science Magazine’s ‘Breakthrough of the Year 2008’ and Nature’s ‘Method of the Year 2009.’ Their discoverer, Shinya Yamanaka, shared the Lasker Award last year and is no doubt touted for a future Nobel Prize. ‘They’ are…

Digital polymerase chain reaction; new diagnostic opportunities

22 February 2010 | By

LGC is an international science-based company located in South West London. A progressive and innovative enterprise, LGC operates in socially responsible fields underpinning the health, safety and security of the public, and regulation and enforcement for UK government departments and blue chip clients. Our products and services enable our customers…

DNA sequencing
DNA sequencing

Applying statistical inference in genomics with evidence based pathways: Towards elucidating new functional correlations of biomarkers

22 February 2010 | By Peter Ghazal, Professor of Molecular Genetics and Biomedicine, University of Edinburgh and Head of Division of Pathway Medicine and Associate Director of Centre for Systems Biology, Edinburgh, Al Ivens, Head of Data Analysis, Fios Genomics Ltd and Thorsten Forster, Statistical Bioinformatician, Division of Pathway Medicine, University of Edinburgh

In conventional pharmacogenomic studies, genetic polymorphisms (including single nucleotide and copy number variations) are elucidated from case-control distribution of individuals usually representing ethnicity, severity of disease, and positive or negative response to treatment. However, the interpretation of a single genetic marker in this context is complicated, as the same marker…

The changing landscape of automation in pre-clinical drug discovery

22 February 2010 | By

Over the past decade we have seen a significant realignment of activities associated with drug discovery and this will continue for a multitude of reasons. Within the pharmaceutical industry we have seen significant changes e.g. a decrease in the numbers of drugs that are being approved by the regulatory authorities…

2009: A landmark year for stem cells

22 February 2010 | By

It would be fair to say that these past 12 months have been a watershed year for stem cell science. In years to come we may look back on 2009 and recognise it as the year in which nascent areas of science, medicine and technology came together to slowly nudge…

Professor Conan Fee, University of Canterbury, New Zealand
Professor Conan Fee, University of Canterbury, New Zealand

Protein PEGylation: An overview of chemistry and process considerations

22 February 2010 | By ,

Innovative drug delivery technologies are key components of drug development, with commercial and intellectual values. PEGylation is an excellent example of a delivery system that has scientific and multi-billion dollar commercial importance due to the remarkable improvement in the circulatory half lives of therapeutics, especially for proteins and peptides but…

Microbiological quality for non-sterile drug product for the 21st century

22 February 2010 | By

For decades microbiological quality has remain dormant while the pharmaceutical industry has continued to evolve. Compendial methods and limits, while now generally harmonised throughout the world, still reflect the same methods utilised 100 years ago. Although there is more clarification around the number and types of organisms permitted in products…

Contributing to the Sustainability of the UK Chemicals and Pharmaceuticals Industries

22 February 2010 | By

The Centre for Process Analytics and Control Technology (CPACT) is a unique industry-driven multi-disciplinary research and development club that was formed in 1997 by the Departments of Pure and Applied Chemistry at the University of Strathclyde, the Department of Chemical and Process Engineering at the University of Newcastle and the…